Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results
July 21, 2020 08:30 ET
|
Avenue Therapeutics
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Publications in Peer-Reviewed Journals
June 05, 2020 08:30 ET
|
Avenue Therapeutics
NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders
May 29, 2020 08:30 ET
|
Avenue Therapeutics
NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
May 11, 2020 07:30 ET
|
Avenue Therapeutics
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters
April 23, 2020 08:30 ET
|
Avenue Therapeutics
NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
March 30, 2020 07:30 ET
|
Avenue Therapeutics
NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA
February 13, 2020 08:00 ET
|
Avenue Therapeutics
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol
December 11, 2019 08:30 ET
|
Avenue Therapeutics
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
November 04, 2019 07:30 ET
|
Avenue Therapeutics
NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development
October 28, 2019 08:30 ET
|
Avenue Therapeutics
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, announced...